Chronic Hepatitis D Infection Clinical Trial
Official title:
A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05827146 -
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
|
Phase 2 | |
| Completed |
NCT02430181 -
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
|
Phase 2 | |
| Recruiting |
NCT05760300 -
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|
||
| Recruiting |
NCT05718700 -
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
|
||
| Completed |
NCT02637999 -
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Completed |
NCT02430194 -
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
|
Phase 2 |